Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.45 |
| ▸ | POLQ | O75417 | 2/20 | 0.42 |
| ▸ | PDK2 | Q15119 | 2/20 | 0.40 |
| ▸ | PDK4 | Q16654 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | TP53 | P04637 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.39 |
| ▸ | HPGD | P15428 | 1/20 | 0.39 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.39 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | CASP1 | P29466 | 1/20 | 0.39 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
| ▸ | CASP7 | P55210 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
| ▸ | HRH1 | P35367 | 1/20 | 0.39 |
| ▸ | ADRA1B | P35368 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2735150 | 0.97 | KDM4E (0.45) | KDM4EPOLQPDK2PDK4ALDH1A1 | |
| SCHEMBL2735250 | 0.86 | RAPGEF4 (0.45) | KDM4EPOLQPDK2PDK4ALDH1A1 | |
| SCHEMBL2735172 | 0.84 | PDE9A (0.46) | KDM4EPOLQPDK2PDK4ALDH1A1 | |
| SCHEMBL2735148 | 0.84 | KDM4E (0.46) | KDM4EALDH1A1HPGDHSD17B10PDE9A | |
| SCHEMBL2735215 | 0.83 | CHUK (0.39) | KDM4EPDK2PDK4ALDH1A1USP2 | |
| SCHEMBL2735203 | 0.83 | CHUK (0.39) | KDM4EPDK2PDK4ALDH1A1USP2 | |
| SCHEMBL2735146 | 0.82 | KDM4E (0.45) | KDM4EPOLQALDH1A1TP53MAPT | |
| SCHEMBL2735151 | 0.81 | KDM4E (0.53) | KDM4EALDH1A1MAPTTHRBHPGD | |
| SCHEMBL8284874 | 0.81 | PDE9A (0.45) | KDM4EPDK2PDK4ALDH1A1USP2 | |
| SCHEMBL2735149 | 0.81 | KDM4E (0.48) | KDM4EALDH1A1USP2MAPTHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1709009-B1 | 6-AMINO-5-CYANO-PYRIMIDINE-4-ONES USED FOR IMPROVING PERCEPTION, POWER OF CONCENTRATION, LEARNING EFFICIENCY, AND/OR MEMORY POWER | BOEHRINGER INGELHEIM INT (DE) | 2013-11-20 | — | — | EP | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| US-8431573-B2 | Cyanopyrimidinones | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2013-04-30 | — | — | US | disclosed |
| CN-102382063-A | 6-amino-5-cyano-pyrimidine-4-ones compound used for improving perception, power of concentration, learning efficiency, and/or memory power | BOEHRINGER INGELHEIM INT | 2012-03-21 | — | — | CN | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| US-8088769-B2 | e.g. 2-(3,4-Dichlorophenyl)ethanamidine hydrochloride; phosphodiesterases inhibitor; learning enhancement, cognition activator; improving perception, concentration, or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2012-01-03 | — | — | US | disclosed |
| CN-1926117-B | 6-amino-5-cyano-pyrimidin-4-ones for improved perception, attention, learning efficiency, and/or memory | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-12-07 | — | — | CN | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20110207735-A1 | CYANOPYRIMIDINONES | HENDRIX MARTIN | 2011-08-25 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| US-20080255118-A1 | Cyanopyrimidinones | BAYER HEALTHCARE AG (DE) | 2008-10-16 | — | — | US | disclosed |
| CN-1926117-A | 6-amino-5-cyano-pyrimidin-4-ones for improved perception, attention, learning efficiency, and/or memory | BAYER HEALTHCARE AG (DE) | 2007-03-07 | — | — | CN | disclosed |
| WO-2005068436-A1 | 6-AMINO-5-CYANO-PYRIMIDINE-4-ONES USED FOR IMPROVING PERCEPTION, POWER OF CONCENTRATION, LEARNING EFFICIENCY, AND/OR MEMORY POWER | BAYER HEALTHCARE AG (DE) | 2005-07-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080255118-A1 | Cyanopyrimidinones | CACYBP, CHRM4, CHRNA4 | KDM4E 1288/4885POLQ 3483/4885PDK2 1022/4885 |
| US-20110207735-A1 | CYANOPYRIMIDINONES | CACYBP, CHRM4, CHRNA4 | KDM4E 1288/4885POLQ 3483/4885PDK2 1022/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.